Randomized, double-blind, placebo-controlled study of recombinant B-type natriuretic peptide in subjects with acute decompensated congestive heart failure

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000284

Enrollment

Unknown

Registered

2008-11-04

Start date

2007-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congestive heart failure

Interventions

BNP group:tthe dose is a 2 ug/kg i.v. bolus loading dose followed by continuous infusion at 0.01 ug/kg/min.

placebo group:matching placebo. dose is identical to BNP group.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Dyspnea at rest or dyspnea with minimal activity; 2. Tachypnea with respiratory rate >= 20 breaths per minutes, or pulmonary congestion/edema with rales or crackles/crepitations at least one-third above lung base; 3. Chest X-ray with pulmonary congestion/edema, or B-type natriuretic peptide >= 400pg/ml, or ejection fraction < 40%.

Exclusion criteria

Exclusion criteria: COPD; BNP is within normal limits; acute or chronic infectious diseases; acute coronary syndrome; hypotension; gastrointestinal diseases; severe renal diseases; severe liver diseases; anemia; the life expectancy in less than 6 months; unwillingness or inability to comply with the study.

Design outcomes

Primary

Measure	Time frame
HF symptoms;Long-term outcome;	—

Countries

China

Contacts

Public ContactZhifu Guo

guozhifu@126.com+86 021 25072064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026